鼻咽頭炎(風邪)(Nasopharyngitis (Common Cold)):治療薬パイプラインレビュー

◆英語タイトル:Nasopharyngitis (Common Cold) - Pipeline Review, H2 2018
◆商品コード:GMDHC10659IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2018年7月17日
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site PriceUSD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise PriceUSD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Nasopharyngitis (Common Cold) – Pipeline Review, H2 2018
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngitis (Common Cold) – Pipeline Review, H2 2018, provides an overview of the Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline landscape.

Nasopharyngitis also known as common cold is an infectious, inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Nasopharyngitis (Common Cold) – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nasopharyngitis (Common Cold) – Overview
Nasopharyngitis (Common Cold) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Nasopharyngitis (Common Cold) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nasopharyngitis (Common Cold) – Companies Involved in Therapeutics Development
Charleston Laboratories Inc
Karo Pharma AB
Orbis Biosciences Inc
Tris Pharma Inc
Nasopharyngitis (Common Cold) – Drug Profiles
Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-05 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-06 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-07 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-08 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guaifenesin ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydrocodone bitartrate + Undisclosed drug – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-1088 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NORS-4002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORB-110 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MAPK13 for Asthma and Cold – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-268A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nasopharyngitis (Common Cold) – Dormant Projects
Nasopharyngitis (Common Cold) – Discontinued Products
Nasopharyngitis (Common Cold) – Product Development Milestones
Featured News & Press Releases
Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
Oct 10, 2013: Spriaso completes FDA Meeting on Tuxarin ER
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Nasopharyngitis (Common Cold), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories Inc, H2 2018
Nasopharyngitis (Common Cold) - Pipeline by Karo Pharma AB, H2 2018
Nasopharyngitis (Common Cold) - Pipeline by Orbis Biosciences Inc, H2 2018
Nasopharyngitis (Common Cold) - Pipeline by Tris Pharma Inc, H2 2018
Nasopharyngitis (Common Cold) - Dormant Projects, H2 2018
Nasopharyngitis (Common Cold) - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Nasopharyngitis (Common Cold), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[鼻咽頭炎(風邪)(Nasopharyngitis (Common Cold)):治療薬パイプラインレビュー]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆